View Financial HealthRegnum 配当と自社株買い配当金 基準チェック /06Regnum配当金を支払った記録がありません。主要情報n/a配当利回りn/aバイバック利回り総株主利回りn/a将来の配当利回りn/a配当成長n/a次回配当支払日n/a配当落ち日n/a一株当たり配当金n/a配当性向n/a最近の配当と自社株買いの更新更新なしすべての更新を表示Recent updatesお知らせ • Jun 01Regnum Corp. Announces Resignation of Anne Kirby as Sole Member of Board of DirectorsOn May 23, 2023, Anne Kirby provided formal notice of her resignation as Chief Executive Officer and as the sole member of the board of directors of Regnum Corp. (the “Company”). Ms. Kirby’s resignation was for personal reasons and not a result of a disagreement relating to the Company’s operations, policies or practices. The Company and its majority shareholder have begun the process to fill the board and officer vacancies with suitable candidates.お知らせ • Aug 17Regnum Corp. announced delayed 10-Q filingOn 08/16/2022, Regnum Corp. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • May 17Regnum Corp. announced delayed 10-Q filingOn 05/16/2022, Regnum Corp. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • Apr 01Regnum Corp. announced delayed annual 10-K filingOn 03/31/2022, Regnum Corp. announced that they will be unable to file their next 10-K by the deadline required by the SEC.お知らせ • Sep 02SevenScore Pharmaceuticals, LLC cancelled the acquisition of Regnum Corp. (OTCPK:RGMP) from Phoenixus AG in a reverse merger transaction.SevenScore Pharmaceuticals LLC made a proposal to acquire Regnum Corp. (OTCPK:RGMP) from Phoenixus AG and others in a reverse merger transaction for $9.8 million on April 7, 2021. SevenScore Pharmaceuticals LLC entered into an agreement to acquire Regnum Corp. from Phoenixus AG and others in a reverse merger transaction on May 13, 2021. Phoenixus AG (“PAG”) owns approximately 98.9% stake in Regnum. Upon closing, membership interests in SevenScore will be converted into the right to receive an aggregate of 25.9 million shares of common stock of Regnum. Upon effectiveness of the Merger, (i) each share of Regnum Common Stock issued and outstanding and owned by PAG as of immediately prior thereto shall be cancelled and extinguished without any conversion thereof, and (ii) 22,730,409 shares of Regnum Common Stock will be owned by PAG as a result of conversion of SevenScore membership interests; (ii) 3,147,759 shares of RGMP Common Stock being owned by several other SevenScore members; and (iii) 250,000 shares of Regnum Common Stock being owned by the Regnum shareholders, other than PAG, prior to effectiveness of the Merger. The equity holders, or members, of SevenScore will receive a majority of the shares of common stock of Regnum in the merger. The completion of the Merger is subject to satisfaction to submit a Company Related Action Notification in accordance with Financial Industry Regulatory Authority (FINRA) Rule 6490. The board of directors of Regnum and SevenScore have unanimously approved the transaction. PAG, the majority shareholder of Regnum also approved the transaction. SevenScore Pharmaceuticals, LLC cancelled the acquisition of Regnum Corp. (OTCPK:RGMP) from Phoenixus AG in a reverse merger transaction on September 1, 2021. No fees or penalties were paid in connection with the termination of the agreement.お知らせ • Aug 18Regnum Corp. announced delayed 10-Q filingOn 08/17/2021, Regnum Corp. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • Apr 03Regnum Corp. announced delayed annual 10-K filingOn 04/01/2021, Regnum Corp. announced that they will be unable to file their next 10-K by the deadline required by the SEC.お知らせ • Aug 18Regnum Corp. announced delayed 10-Q filingOn 08/17/2020, Regnum Corp. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.決済の安定と成長配当データの取得安定した配当: RGMPの 1 株当たり配当が過去に安定していたかどうかを判断するにはデータが不十分です。増加する配当: RGMPの配当金が増加しているかどうかを判断するにはデータが不十分です。配当利回り対市場Regnum 配当利回り対市場RGMP 配当利回りは市場と比べてどうか？セグメント配当利回り会社 (RGMP)n/a市場下位25% (US)1.4%市場トップ25% (US)4.3%業界平均 (Pharmaceuticals)2.1%アナリスト予想 (RGMP) (最長3年)n/a注目すべき配当: RGMPは最近配当金を報告していないため、配当金支払者の下位 25% に対して同社の配当利回りを評価することはできません。高配当: RGMPは最近配当金を報告していないため、配当金支払者の上位 25% に対して同社の配当利回りを評価することはできません。株主への利益配当収益カバレッジ: RGMPの 配当性向 を計算して配当金の支払いが利益で賄われているかどうかを判断するにはデータが不十分です。株主配当金キャッシュフローカバレッジ: RGMPが配当金を報告していないため、配当金の持続可能性を計算できません。高配当企業の発掘7D1Y7D1Y7D1YUS 市場の強力な配当支払い企業。View Management企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2024/10/09 20:47終値2024/07/12 00:00収益2023/03/31年間収益2022/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Regnum Corp. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
お知らせ • Jun 01Regnum Corp. Announces Resignation of Anne Kirby as Sole Member of Board of DirectorsOn May 23, 2023, Anne Kirby provided formal notice of her resignation as Chief Executive Officer and as the sole member of the board of directors of Regnum Corp. (the “Company”). Ms. Kirby’s resignation was for personal reasons and not a result of a disagreement relating to the Company’s operations, policies or practices. The Company and its majority shareholder have begun the process to fill the board and officer vacancies with suitable candidates.
お知らせ • Aug 17Regnum Corp. announced delayed 10-Q filingOn 08/16/2022, Regnum Corp. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • May 17Regnum Corp. announced delayed 10-Q filingOn 05/16/2022, Regnum Corp. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • Apr 01Regnum Corp. announced delayed annual 10-K filingOn 03/31/2022, Regnum Corp. announced that they will be unable to file their next 10-K by the deadline required by the SEC.
お知らせ • Sep 02SevenScore Pharmaceuticals, LLC cancelled the acquisition of Regnum Corp. (OTCPK:RGMP) from Phoenixus AG in a reverse merger transaction.SevenScore Pharmaceuticals LLC made a proposal to acquire Regnum Corp. (OTCPK:RGMP) from Phoenixus AG and others in a reverse merger transaction for $9.8 million on April 7, 2021. SevenScore Pharmaceuticals LLC entered into an agreement to acquire Regnum Corp. from Phoenixus AG and others in a reverse merger transaction on May 13, 2021. Phoenixus AG (“PAG”) owns approximately 98.9% stake in Regnum. Upon closing, membership interests in SevenScore will be converted into the right to receive an aggregate of 25.9 million shares of common stock of Regnum. Upon effectiveness of the Merger, (i) each share of Regnum Common Stock issued and outstanding and owned by PAG as of immediately prior thereto shall be cancelled and extinguished without any conversion thereof, and (ii) 22,730,409 shares of Regnum Common Stock will be owned by PAG as a result of conversion of SevenScore membership interests; (ii) 3,147,759 shares of RGMP Common Stock being owned by several other SevenScore members; and (iii) 250,000 shares of Regnum Common Stock being owned by the Regnum shareholders, other than PAG, prior to effectiveness of the Merger. The equity holders, or members, of SevenScore will receive a majority of the shares of common stock of Regnum in the merger. The completion of the Merger is subject to satisfaction to submit a Company Related Action Notification in accordance with Financial Industry Regulatory Authority (FINRA) Rule 6490. The board of directors of Regnum and SevenScore have unanimously approved the transaction. PAG, the majority shareholder of Regnum also approved the transaction. SevenScore Pharmaceuticals, LLC cancelled the acquisition of Regnum Corp. (OTCPK:RGMP) from Phoenixus AG in a reverse merger transaction on September 1, 2021. No fees or penalties were paid in connection with the termination of the agreement.
お知らせ • Aug 18Regnum Corp. announced delayed 10-Q filingOn 08/17/2021, Regnum Corp. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • Apr 03Regnum Corp. announced delayed annual 10-K filingOn 04/01/2021, Regnum Corp. announced that they will be unable to file their next 10-K by the deadline required by the SEC.
お知らせ • Aug 18Regnum Corp. announced delayed 10-Q filingOn 08/17/2020, Regnum Corp. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.